Business Description
Calliditas Therapeutics AB
ISIN : US13124Q1067
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.8 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 8.46 | |||||
Debt-to-EBITDA | -2.49 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 2.85 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 957.8 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | -2 | |||||
3-Year FCF Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -36.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 57.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.32 | |||||
9-Day RSI | 56.05 | |||||
14-Day RSI | 56.27 | |||||
6-1 Month Momentum % | -0.6 | |||||
12-1 Month Momentum % | -1.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.69 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 1.99 | |||||
Days Inventory | 116.33 | |||||
Days Sales Outstanding | 44.59 | |||||
Days Payable | 475.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -5.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 95.01 | |||||
Operating Margin % | -33.04 | |||||
Net Margin % | -40.03 | |||||
FCF Margin % | -30.34 | |||||
ROE % | -160.04 | |||||
ROA % | -30.56 | |||||
ROIC % | -74.3 | |||||
ROC (Joel Greenblatt) % | -752.57 | |||||
ROCE % | -30.09 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 909.09 | |||||
PS Ratio | 4.69 | |||||
PB Ratio | 51.14 | |||||
EV-to-EBIT | -15.57 | |||||
EV-to-Forward-EBIT | 80.02 | |||||
EV-to-EBITDA | -15.57 | |||||
EV-to-Forward-EBITDA | 80.02 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-Forward-Revenue | 3.31 | |||||
EV-to-FCF | -15.84 | |||||
Earnings Yield (Greenblatt) % | -6.42 | |||||
FCF Yield % | -6.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Calliditas Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 114.468 | ||
EPS (TTM) (€) | -1.696 | ||
Beta | 1.78 | ||
Volatility % | 59.08 | ||
14-Day RSI | 56.27 | ||
14-Day ATR (€) | 0.993406 | ||
20-Day SMA (€) | 18.89 | ||
12-1 Month Momentum % | -1.19 | ||
52-Week Range (€) | 13.9 - 26 | ||
Shares Outstanding (Mil) | 26.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Calliditas Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Calliditas Therapeutics AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Calliditas Therapeutics AB Frequently Asked Questions
What is Calliditas Therapeutics AB(FRA:LC8A)'s stock price today?
When is next earnings date of Calliditas Therapeutics AB(FRA:LC8A)?
Does Calliditas Therapeutics AB(FRA:LC8A) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |